ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

DMAC vs OVID // FREE CASH FLOW YIELD

DiaMedica Therapeutics Inc. (NASDAQ) VS. Ovid Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: DMAC 3 — OVID 2
▲ FREE CASH FLOW YIELD LEADER: DMAC
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (DMAC VS. OVID) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC DMAC OVID SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -28.50% -6.50 OVID /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield ACTIVE -5.67% -7.67% +2.00 DMAC /fcf-yield <GO>
Operating Margin — -60.00% — TIE /operating-margins <GO>
Net Profit Margin — -60.00% — TIE /net-margins <GO>
Revenue Growth (YoY) — 180.00% — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — 11.46 — TIE /balance-sheet <GO>
Piotroski F-Score Quality 2/9 3/9 -1.00 OVID /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 61.0 55.8 +5.20 DMAC /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $498.8M $496.1M $2.8M DMAC /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR DMAC REV OVID REV DMAC GROSS % OVID GROSS % DMAC FCF OVID FCF
FY 2025 $96.3M $7.3M — — -$29.1M -$38.3M
FY 2024 $74.7M $566.0K — — -$22.1M -$56.0M
FY 2023 $59.5M $392.0K — — -$18.7M -$45.8M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
DMAC // BETA —
OVID // BETA —